Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Myeloid-Derived Suppressor Cells (MDSC) Are Effectors of Bone Marrow Suppression in Lower Risk Myelodysplastic Syndromes (MDS).

Sheng Wei, MD, Xianghong Chen, PhD, Kathy Rocha, Dahui Qi, MD, Jianguo Tao, MD, PhD, Nicole Gjertsen, Junmin Zhou, Ph.D, Jinhong Liu, M.D., Dmitry Gabrilovich, MD, PhD, P.K. Epling-Burnette, PhD, Julie Y Djeu, PhD, Alan F. List, MD

Blood (2009) 114 (22): 597.

https://doi.org/10.1182/blood.V114.22.597.597

Published: 2009

Journal Articles

Genetic Disparities in Killer Cell Immunoglobulin-Like Receptors (KIR) and MHC Class I in Bone Marrow Failure Syndromes

P.K. Epling-Burnette, PhD, Jeffrey S. Painter, BS, H.-S. Lee, PhD, Jong Park, Michael Clemente, MS, Christine O’Keefe, MD, Tie-Ying Wei, BS, Sheng Wei, MD, Jaroslaw Maciejewski, Thomas P. Loughran, Jr., MD, Ron Paquette, MD, Alan F. List, MD, Julie Y Djeu, PhD

Blood (2008) 112 (11): 4121.

https://doi.org/10.1182/blood.V112.11.4121.4121

Published: 2008

Journal Articles

Reduced Natural Killer Function Accompanies MDS Disease Progression and Is Restored by Lenalidomide (CC5013, Revlimid®) Via a Mechanism Divergent from Interleukin-2 (IL-2).

P.K. Epling-Burnette, PhD, Fanqi Bai, MD, Jeffrey S. Painter, BS, Rollison Dana, PhD, JianXiang Zou, MD, Edna Ku, MD, Bin Zhong, BS, Sheng Wei, MD, Julie Y. Djeu, PhD, Alan F. List, MD

Blood (2006) 108 (11): 2651.

https://doi.org/10.1182/blood.V108.11.2651.2651

Published: 2006

Journal Articles

Natural Killer Cells with NKDG2D Cytotoxicity but NKp30-Dull Phenotype Predominate in Myelodysplastic Syndrome (MDS).

Fanqi Bai, MD, Jeffrey S. Painter, Cantor Alan, PhD, Zou JianXiang, MD, Sheng Wei, MD, Julie Y. Djeu, PhD, Alan F. List, MD, P.K. Epling-Burnette, PhD

Blood (2005) 106 (11): 3436.

https://doi.org/10.1182/blood.V106.11.3436.3436

Published: 2005

Journal Articles

Lenalidomide Effects on NK Function in Patients with Myelodysplastic Syndrome (MDS).

P.K. Epling-Burnette, PhD, Fanqi Bai, MD, Jeffrey S. Painter, Julie Y. Djeu, PhD, Alan F. List, MD

Blood (2005) 106 (11): 3437.

https://doi.org/10.1182/blood.V106.11.3437.3437

Published: 2005

NARROW

Myeloid-Derived Suppressor Cells (MDSC) Are Effectors of Bone Marrow Suppression in Lower Risk Myelodysplastic Syndromes (MDS).

Genetic Disparities in Killer Cell Immunoglobulin-Like Receptors (KIR) and MHC Class I in Bone Marrow Failure Syndromes

Reduced Natural Killer Function Accompanies MDS Disease Progression and Is Restored by Lenalidomide (CC5013, Revlimid®) Via a Mechanism Divergent from Interleukin-2 (IL-2).

Natural Killer Cells with NKDG2D Cytotoxicity but NKp30-Dull Phenotype Predominate in Myelodysplastic Syndrome (MDS).

Lenalidomide Effects on NK Function in Patients with Myelodysplastic Syndrome (MDS).

Email alerts

ASH Publications

American Society of Hematology

Myeloid-Derived Suppressor Cells (MDSC) Are Effectors of Bone Marrow Suppression in Lower Risk Myelodysplastic Syndromes (MDS).

Genetic Disparities in Killer Cell Immunoglobulin-Like Receptors (KIR) and MHC Class I in Bone Marrow Failure Syndromes

Reduced Natural Killer Function Accompanies MDS Disease Progression and Is Restored by Lenalidomide (CC5013, Revlimid®) Via a Mechanism Divergent from Interleukin-2 (IL-2).

Natural Killer Cells with NKDG2D Cytotoxicity but NKp30-Dull Phenotype Predominate in Myelodysplastic Syndrome (MDS).

Lenalidomide Effects on NK Function in Patients with Myelodysplastic Syndrome (MDS).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only